GSK Stock Recent News

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.

GSK has delivered encouraging updates from ongoing trials of its vaccines for Shingles and Gonorrhoea. In the follow-up Zoster trial for the now on-sale Shingrix vaccine, efficacy was more than 80% for patients over 50 between 6-11 years after the jab with no new safety issues identified.

British drugmaker GSK said on Wednesday long-term data showed that its blockbuster shingles vaccine, Shingrix, had 79.7% efficacy in participants aged 50 years and above, six to 11 years after vaccination.

GSK (GSK) closed at $40.80 in the latest trading session, marking a +0.27% move from the prior day.

GSK (GSK) concluded the recent trading session at $41.19, signifying a +0.81% move from its prior day's close.

GSK (GSK) concluded the recent trading session at $41.79, signifying a -1.49% move from its prior day's close.

Recently, Zacks.com users have been paying close attention to Glaxo (GSK). This makes it worthwhile to examine what the stock has in store.

GSK (GSK) closed at $42.99 in the latest trading session, marking a +0.47% move from the prior day.

GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.